Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 970

2.

Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.

Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):695-704. doi: 10.1097/MEG.0b013e32832e0a18.

PMID:
19543101
4.

E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.

Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, Avnstrøm S, Langholz E, O'Morain C, Lynge E, Munkholm P.

Gut. 2010 Dec;59(12):1652-61. doi: 10.1136/gut.2010.220160.

PMID:
21071584
5.

eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.

Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Végh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P.

Inflamm Bowel Dis. 2014 Dec;20(12):2276-85. doi: 10.1097/MIB.0000000000000199.

PMID:
25248002
7.

Challenges in the design of a Home Telemanagement trial for patients with ulcerative colitis.

Cross RK, Finkelstein J.

Clin Trials. 2009 Dec;6(6):649-57. doi: 10.1177/1740774509346978. Epub 2009 Oct 12.

PMID:
19822631
8.
9.

eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease.

Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S, Knudsen T, Thorsgaard N, Munkholm P.

Aliment Pharmacol Ther. 2012 Nov;36(9):840-9.

10.

Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.

Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD.

BMC Gastroenterol. 2012 Sep 24;12:132. doi: 10.1186/1471-230X-12-132.

11.

Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial.

Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF.

Inflamm Bowel Dis. 2011 Sep;17(9):1874-81. doi: 10.1002/ibd.21570. Epub 2011 Jan 6.

PMID:
21830265
12.

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.

Higgins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV.

Aliment Pharmacol Ther. 2009 Feb 1;29(3):247-57. doi: 10.1111/j.1365-2036.2008.03865.x. Epub 2008 Oct 7. Review.

13.

Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.

Tindall WN, Boltri JM, Wilhelm SM.

J Manag Care Pharm. 2007 Sep;13(7 Suppl A):S2-12; quiz S13-4.

PMID:
17874873
14.

Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.

Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W.

J Crohns Colitis. 2017 Sep 1;11(9):1052-1062. doi: 10.1093/ecco-jcc/jjx062.

PMID:
28486634
15.

Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.

Robinson A, Thompson DG, Wilkin D, Roberts C; Northwest Gastrointestinal Research Group.

Lancet. 2001 Sep 22;358(9286):976-81.

PMID:
11583752
16.

Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.

Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Høie O, Rydning A, Vatn MH; IBSEN II Study Group.

Scand J Gastroenterol. 2011 Sep;46(9):1081-91. doi: 10.3109/00365521.2011.584897. Epub 2011 May 30.

PMID:
21619483
17.

Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey.

Sung JJ, Kamm MA, Marteau P.

J Gastroenterol Hepatol. 2010 Jan;25(1):183-93. doi: 10.1111/j.1440-1746.2009.06024.x. Epub 2009 Nov 19.

PMID:
19929931
18.

Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis.

Lasson A, Simrén M, Stotzer PO, Isaksson S, Ohman L, Strid H.

Inflamm Bowel Dis. 2013 Mar;19(3):576-81. doi: 10.1097/MIB.0b013e31827e78be.

PMID:
23377170
19.

Guideline adherence and patient satisfaction in the treatment of inflammatory bowel disorders--an evaluation study.

Pieper C, Haag S, Gesenhues S, Holtmann G, Gerken G, Jöckel KH.

BMC Health Serv Res. 2009 Jan 27;9:17. doi: 10.1186/1472-6963-9-17.

20.

Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.

Yamamoto T, Shimoyama T, Matsumoto K.

Aliment Pharmacol Ther. 2015 Sep;42(5):549-58. doi: 10.1111/apt.13308. Epub 2015 Jul 3.

Supplemental Content

Support Center